<p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）在週五發佈的報告中，皇家銀行的投資分析師將其目標價格從 115.00 美元上調至 120.00 美元，Benzinga 報道。該券商目前對這家醫療設備公司的股票給予 “跑贏大盤” 的評級。皇家銀行的目標價格意味着該公司股價有 51.72% 的潛在上漲空間。</p>
<p>其他幾位分析師也對該股票發佈了報告。Canaccord Genuity Group 將 Globus Medical 的目標價格從 105.00 美元上調至 112.00 美元，並在 1 月 9 日的報告中給予該公司 “買入” 評級。Needham &amp; Company LLC 將 Globus Medical 的目標價格從 114.00 美元上調至 117.00 美元，並在週五的報告中給予該公司 “買入” 評級。巴克萊將 Globus Medical 的目標價格從 118.00 美元上調至 123.00 美元，並在 2 月 25 日的報告中給予該公司 “增持” 評級。Piper Sandler 在 1 月 8 日的報告中重申了 “增持” 評級，並將 Globus Medical 的目標價格設定為 115.00 美元（上調自 90.00 美元）。最後，TD Cowen 在 1 月 27 日的報告中將 Globus Medical 的股票評級上調至 “強力買入”。兩位股票研究分析師給予該股票 “強力買入” 評級，九位給予 “買入” 評級，五位給予 “持有” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，平均目標價格為 106.36 美元。</p>
<p>獲取 <strong>Globus Medical</strong> 警報：</p>
<p><strong>閲讀我們關於 Globus Medical 的最新報告</strong></p>
<h2>Globus Medical 股票表現</h2>
<p>週五，NYSE GMED 的股票交易下跌 5.98 美元，跌至 79.09 美元。該公司交易了 2,551,746 股，較其平均交易量 1,233,959 股有所增加。Globus Medical 的 12 個月低點為 51.79 美元，12 個月高點為 101.40 美元。該公司的 50 日移動平均價格為 89.86 美元，200 日移動平均價格為 86.65 美元。該公司的市值為 107 億美元，市盈率為 20.01，市盈增長比率為 2.09，貝塔值為 1.00。</p>
<p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最近在 5 月 7 日發佈了季度財報。這家醫療設備公司報告本季度每股收益為 1.12 美元，超出市場共識預期的 0.92 美元，超出幅度為 0.20 美元。Globus Medical 的股本回報率為 12.57%，淨利潤率為 18.30%。該公司本季度的收入為 7.5985 億美元，而分析師預期為 7.4035 億美元。在去年同期，該公司每股收益為 0.68 美元。與去年同期相比，該公司的季度收入增長了 27.0%。Globus Medical 已將其 2026 財年的指導目標設定為每股收益 4.700-4.800 美元。研究分析師預計 Globus Medical 在當前財年將發佈每股收益 4.46 美元。</p>
<h2>Globus Medical 的內部交易</h2>
<p>在相關消息中，執行副總裁 Kelly Huller 在 2 月 25 日的交易中出售了 20,000 股公司的股票。該股票以平均 94.50 美元的價格出售，總價值為 1,890,000.00 美元。此次出售在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。公司內部人士持有公司 18.38% 的股份。</p>
<h2>對 Globus Medical 的對沖基金看法</h2>
<p>機構投資者最近買入和賣出了該公司的股票。SBI 證券有限公司在第四季度將其在 Globus Medical 的持股增加了 98.2%。SBI 證券有限公司目前持有 337 股該醫療設備公司的股票，價值 29,000 美元，此前在上個季度增持了 167 股。Advisory Services Network LLC 在第三季度獲得了 Globus Medical 的新頭寸，價值約 26,000 美元。EverSource Wealth Advisors LLC 在第二季度將其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 目前持有 462 股該醫療設備公司的股票，價值 27,000 美元，此前在上個季度增持了 197 股。Larson Financial Group LLC 在第四季度將其在 Globus Medical 的持股增加了 83.4%。Larson Financial Group LLC 目前持有 532 股該醫療設備公司的股票，價值 46,000 美元，此前在上個季度增持了 242 股。最後，First Horizon Corp 在第三季度獲得了 Globus Medical 的新頭寸，價值約 31,000 美元。95.16% 的股票由機構投資者和對沖基金持有。</p>
<h2>影響 Globus Medical 的關鍵故事</h2>
<p>以下是本週影響 Globus Medical 的關鍵新聞故事：</p>
<ul>
<li>積極情緒：第一季度業績超出預期並上調 2026 財年每股收益指引——第一季度每股收益為 1.12 美元，超出市場共識，收入同比增長 27%；公司將 2026 財年每股收益指引設定為 4.70–4.80 美元（高於市場共識）。GMED 股票因第一季度業績和收入超預期而上漲</li>
<li>積極情緒：分析師支持提升——Needham 將其目標價上調至 117 美元，並維持買入評級，表明分析師對公司持續信心，並認為當前股價有上漲空間。Benzinga</li>
<li>積極情緒：利潤率擴張和盈利能力——公司報告淨利潤率改善（約 18.3%）和更高的股本回報率，強調了隨着收入增長的經營槓桿。GlobeNewswire 新聞稿</li>
<li>中性情緒：完整電話會議/文字記錄可用——管理層評論（財報電話會議/文字記錄）可以提供關於手術量、積壓訂單和 2026 年節奏的詳細信息；投資者應審查以獲取執行信號。財報文字記錄</li>
<li>中性情緒：覆蓋與分析——多個媒體（Zacks、Seeking Alpha、SeattlePI、MarketBeat）發佈了摘要和指標分析；這些內容細化了預期，但並未改變核心的超預期/指引故事。Zacks 第一季度覆蓋</li>
<li>中性情緒：估值背景——該股票的市盈率約為 20 倍，PEG 約為 2.1；投資者在考慮在積極新聞發佈後購買時，將權衡增長與倍數。MarketBeat 簡介</li>
<li>消極情緒：儘管業績超預期，股價仍下跌——這種差異表明短期獲利了結或更廣泛的市場/行業疲軟；需監測日內流動情況以及在財報發佈窗口後是否繼續疲軟。財報快照</li>
</ul>
<h2>關於 Globus Medical</h2>
<p>(獲取免費報告)</p>
<p>Globus Medical, Inc NYSE: GMED 是一家領先的醫療器械公司，專注於脊柱和骨科應用的肌肉骨骼解決方案。公司成立於 2003 年，由 David C. Paul 創立，總部位於賓夕法尼亞州 Audubon，開發、製造和銷售旨在治療脊柱疾病和促進骨癒合的植入設備和外科器械。其產品組合涵蓋了用於微創和開放手術的解決方案，包括椎間體融合設備、椎弓根螺釘系統和用於增強融合效果的生物製劑。</p>
<p>除了核心脊柱業務外，Globus Medical 還擴展到機器人和導航系統，以支持手術室的精確性和效率。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Globus Medical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Globus Medical 嗎？</h2>
<p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Globus Medical 並不在名單上。</p>
<p>雖然 Globus Medical 目前在分析師中獲得中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Globus醫療

<p>加拿大皇家銀行將 Globus Medical（NYSE:GMED）的目標股價從 115.00 美元上調至 120.00 美元，維持 “跑贏大盤” 的評級。這個新目標暗示與前一交易日收盤價相比有 51.72% 的潛在上漲空間。其他分析師也提高了他們的目標股價，Canaccord Genuity 將其設定為 112.00 美元，Needham 則為 117.00 美元。該股票交易下跌至 79.09 美元，市值為 107 億美元。Globus Medical 報告了強勁的季度收益，收入為 7.5985 億美元，較去年同期增長 27%</p>

<p>Globus Medical (NYSE:GMED - Get Free Report) had its price objective hoisted by investment analysts at Royal Bank Of Canada from $115.00 to $120.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an &#34;outperform&#34; rating on the medical device company's stock. Royal Bank Of Canada's target price points to a potential upside of 51.72% from the company's previous close.</p>
<div class="lb-trans"><p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）在週五發佈的報告中，皇家銀行的投資分析師將其目標價格從 115.00 美元上調至 120.00 美元，Benzinga 報道。該券商目前對這家醫療設備公司的股票給予 “跑贏大盤” 的評級。皇家銀行的目標價格意味着該公司股價有 51.72% 的潛在上漲空間。</p>
</div><p>Several other analysts have also issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the company a &#34;buy&#34; rating in a report on Friday, January 9th. Needham &amp; Company LLC boosted their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a &#34;buy&#34; rating in a report on Friday. Barclays boosted their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, February 25th. Piper Sandler restated an &#34;overweight&#34; rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Finally, TD Cowen upgraded shares of Globus Medical to a &#34;strong-buy&#34; rating in a report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $106.36.</p>
<div class="lb-trans"><p>其他幾位分析師也對該股票發佈了報告。Canaccord Genuity Group 將 Globus Medical 的目標價格從 105.00 美元上調至 112.00 美元，並在 1 月 9 日的報告中給予該公司 “買入” 評級。Needham &amp; Company LLC 將 Globus Medical 的目標價格從 114.00 美元上調至 117.00 美元，並在週五的報告中給予該公司 “買入” 評級。巴克萊將 Globus Medical 的目標價格從 118.00 美元上調至 123.00 美元，並在 2 月 25 日的報告中給予該公司 “增持” 評級。Piper Sandler 在 1 月 8 日的報告中重申了 “增持” 評級，並將 Globus Medical 的目標價格設定為 115.00 美元（上調自 90.00 美元）。最後，TD Cowen 在 1 月 27 日的報告中將 Globus Medical 的股票評級上調至 “強力買入”。兩位股票研究分析師給予該股票 “強力買入” 評級，九位給予 “買入” 評級，五位給予 “持有” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，平均目標價格為 106.36 美元。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Globus Medical</strong> 警報：</p>
</div><p><strong>Read Our Latest Report on Globus Medical</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Globus Medical 的最新報告</strong></p>
</div><h2>Globus Medical Stock Performance</h2>
<div class="lb-trans"><h2>Globus Medical 股票表現</h2>
</div><p>Shares of NYSE GMED traded down $5.98 during trading on Friday, hitting $79.09. 2,551,746 shares of the company were exchanged, compared to its average volume of 1,233,959. Globus Medical has a 12-month low of $51.79 and a 12-month high of $101.40. The company has a fifty day moving average price of $89.86 and a 200-day moving average price of $86.65. The firm has a market capitalization of $10.70 billion, a PE ratio of 20.01, a P/E/G ratio of 2.09 and a beta of 1.00.</p>
<div class="lb-trans"><p>週五，NYSE GMED 的股票交易下跌 5.98 美元，跌至 79.09 美元。該公司交易了 2,551,746 股，較其平均交易量 1,233,959 股有所增加。Globus Medical 的 12 個月低點為 51.79 美元，12 個月高點為 101.40 美元。該公司的 50 日移動平均價格為 89.86 美元，200 日移動平均價格為 86.65 美元。該公司的市值為 107 億美元，市盈率為 20.01，市盈增長比率為 2.09，貝塔值為 1.00。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 EPS. The company's quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts anticipate that Globus Medical will post 4.46 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最近在 5 月 7 日發佈了季度財報。這家醫療設備公司報告本季度每股收益為 1.12 美元，超出市場共識預期的 0.92 美元，超出幅度為 0.20 美元。Globus Medical 的股本回報率為 12.57%，淨利潤率為 18.30%。該公司本季度的收入為 7.5985 億美元，而分析師預期為 7.4035 億美元。在去年同期，該公司每股收益為 0.68 美元。與去年同期相比，該公司的季度收入增長了 27.0%。Globus Medical 已將其 2026 財年的指導目標設定為每股收益 4.700-4.800 美元。研究分析師預計 Globus Medical 在當前財年將發佈每股收益 4.46 美元。</p>
</div><h2>Insider Transactions at Globus Medical</h2>
<div class="lb-trans"><h2>Globus Medical 的內部交易</h2>
</div><p>In related news, EVP Kelly Huller sold 20,000 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 18.38% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Kelly Huller 在 2 月 25 日的交易中出售了 20,000 股公司的股票。該股票以平均 94.50 美元的價格出售，總價值為 1,890,000.00 美元。此次出售在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。公司內部人士持有公司 18.38% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Globus Medical</h2>
<div class="lb-trans"><h2>對 Globus Medical 的對沖基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company's stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Advisory Services Network LLC acquired a new position in Globus Medical in the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after acquiring an additional 197 shares in the last quarter. Larson Financial Group LLC grew its position in Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company's stock valued at $46,000 after acquiring an additional 242 shares in the last quarter. Finally, First Horizon Corp acquired a new position in Globus Medical in the 3rd quarter valued at about $31,000. 95.16% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。SBI 證券有限公司在第四季度將其在 Globus Medical 的持股增加了 98.2%。SBI 證券有限公司目前持有 337 股該醫療設備公司的股票，價值 29,000 美元，此前在上個季度增持了 167 股。Advisory Services Network LLC 在第三季度獲得了 Globus Medical 的新頭寸，價值約 26,000 美元。EverSource Wealth Advisors LLC 在第二季度將其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 目前持有 462 股該醫療設備公司的股票，價值 27,000 美元，此前在上個季度增持了 197 股。Larson Financial Group LLC 在第四季度將其在 Globus Medical 的持股增加了 83.4%。Larson Financial Group LLC 目前持有 532 股該醫療設備公司的股票，價值 46,000 美元，此前在上個季度增持了 242 股。最後，First Horizon Corp 在第三季度獲得了 Globus Medical 的新頭寸，價值約 31,000 美元。95.16% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Key Stories Impacting Globus Medical</h2>
<div class="lb-trans"><h2>影響 Globus Medical 的關鍵故事</h2>
</div><p>Here are the key news stories impacting Globus Medical this week:</p>
<div class="lb-trans"><p>以下是本週影響 Globus Medical 的關鍵新聞故事：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat and raised FY26 EPS guide — Q1 EPS of $1.12 topped consensus and revenue rose 27% y/y; company set FY‑2026 EPS guidance to $4.70–4.80 (above consensus). GMED Stock Rises on Q1 Earnings &amp; Revenue Beat</li>
<li>Positive Sentiment: Analyst support lifted — Needham raised its price target (to $117) and maintained a Buy, signaling continued analyst confidence and added upside vs. the current share price. Benzinga</li>
<li>Positive Sentiment: Margin expansion and profitability — company reported improved net margin (~18.3%) and higher ROE, underlining operating leverage as revenue scales. GlobeNewswire press release</li>
<li>Neutral Sentiment: Full call/transcript available — management commentary (earnings call/transcript) can provide detail on procedure volumes, backlog and 2026 cadence; investors should review for execution signals. Earnings Transcript</li>
<li>Neutral Sentiment: Coverage &amp; analysis — multiple outlets (Zacks, Seeking Alpha, SeattlePI, MarketBeat) ran summaries and metric breakdowns; these refine expectations but don’t change the core beat/guidance story. Zacks Q1 coverage</li>
<li>Neutral Sentiment: Valuation context — the stock trades at roughly a ~20x P/E with PEG ~2.1; investors will weigh growth vs. multiple when deciding to buy after the run of positive news. MarketBeat profile</li>
<li>Negative Sentiment: Shares trading lower despite the beat — that divergence suggests short‑term profit taking or broader market/sector weakness; monitor intraday flow and whether weakness extends after the post‑earnings window. Earnings snapshot</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：第一季度業績超出預期並上調 2026 財年每股收益指引——第一季度每股收益為 1.12 美元，超出市場共識，收入同比增長 27%；公司將 2026 財年每股收益指引設定為 4.70–4.80 美元（高於市場共識）。GMED 股票因第一季度業績和收入超預期而上漲</li>
<li>積極情緒：分析師支持提升——Needham 將其目標價上調至 117 美元，並維持買入評級，表明分析師對公司持續信心，並認為當前股價有上漲空間。Benzinga</li>
<li>積極情緒：利潤率擴張和盈利能力——公司報告淨利潤率改善（約 18.3%）和更高的股本回報率，強調了隨着收入增長的經營槓桿。GlobeNewswire 新聞稿</li>
<li>中性情緒：完整電話會議/文字記錄可用——管理層評論（財報電話會議/文字記錄）可以提供關於手術量、積壓訂單和 2026 年節奏的詳細信息；投資者應審查以獲取執行信號。財報文字記錄</li>
<li>中性情緒：覆蓋與分析——多個媒體（Zacks、Seeking Alpha、SeattlePI、MarketBeat）發佈了摘要和指標分析；這些內容細化了預期，但並未改變核心的超預期/指引故事。Zacks 第一季度覆蓋</li>
<li>中性情緒：估值背景——該股票的市盈率約為 20 倍，PEG 約為 2.1；投資者在考慮在積極新聞發佈後購買時，將權衡增長與倍數。MarketBeat 簡介</li>
<li>消極情緒：儘管業績超預期，股價仍下跌——這種差異表明短期獲利了結或更廣泛的市場/行業疲軟；需監測日內流動情況以及在財報發佈窗口後是否繼續疲軟。財報快照</li>
</ul>
</div><h2>About Globus Medical</h2>
<div class="lb-trans"><h2>關於 Globus Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.</p>
<div class="lb-trans"><p>Globus Medical, Inc NYSE: GMED 是一家領先的醫療器械公司，專注於脊柱和骨科應用的肌肉骨骼解決方案。公司成立於 2003 年，由 David C. Paul 創立，總部位於賓夕法尼亞州 Audubon，開發、製造和銷售旨在治療脊柱疾病和促進骨癒合的植入設備和外科器械。其產品組合涵蓋了用於微創和開放手術的解決方案，包括椎間體融合設備、椎弓根螺釘系統和用於增強融合效果的生物製劑。</p>
</div><p>In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.</p>
<div class="lb-trans"><p>除了核心脊柱業務外，Globus Medical 還擴展到機器人和導航系統，以支持手術室的精確性和效率。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Globus Medical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Globus Medical 嗎？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Globus Medical 並不在名單上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Globus Medical 目前在分析師中獲得中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Globus Medical (NYSE:GMED) Given New $120.00 Price Target at Royal Bank Of Canada

Market Beat

加拿大皇家銀行

加拿大帝國商業銀行

Bank7

Blaize

Zenas Biopharma

Zimmer Biomet

Nano Labs

Genuit Group PLC

凱雷集團

Capital Group New Geography Equity ETF

CF實業

Landbridge Co LLC

New England Real Asso

Newton Golf Company

巴克萊銀行

Piper Sandler Cos

Toronto Dominion Bank

蒙特利爾銀行

美國股票 MarketBeta ETF - Goldman Sachs

MarketWise

Value Line

SBI Holdings, Inc.

SBI Insurance Group Co., Ltd.

San Holdings, Inc. (Japan)

Advantage Solutions

PMV Adaptive Risk Parity ETF

Network 1 Tech

能源方案

Everquote

WealthNavi, Inc.

萊克蘭金融

Clarkson PLC

Donnelley Financial Solution

第一地平線

BLAIZE HOLDINGS INC C/WTS 13/01/2030 (TO PUR COM)

ADVANTAGE SOLUTIONS INC C/WTS 28/10/2025(TO PUR COM)

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

Globus Medical（紐約證券交易所代碼：GMED）被加拿大皇家銀行設定了新的 120.00 美元目標價